Table 5.
Changes in BTMs at different time points after treatment.
| Treatment time | No. | Gender (M/F) | Age of onset (years) a | Age at treatment (years) a | Serum ALP (U/L) | Serum β-CTX (ng/L) | Serum OC (ng/mL) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline b | treatment b | Change (%) | Baseline b | treatment b | Change (%) | Baseline b | Treatment b | Change (%) | |||||
| 3-month treatment c | 6 | 5/1 | 37.00 ± 18.30 (29-84) | 49.33 ± 19.67 (7-54) | 484.00 (180.00-1206.00) | 147.50 (65.75-437.25) * | -57.4 | 1734.50 (642.45-2913.25) | 688.35 (80.5425-1740) * | -65.1 | 89.90 (28.64-161.22) | 50.80 (19.13-132.13) * | -28.0 |
| 6-month treatment c | 12 | 5/7 | 41.25 ± 18.64 (12-79-) | 51.83 ± 11.28 (34-74) | 177.50 (127.50-332.25) | 69.50 (53.50-124.00) * | -59.7 | 882.10 (605.25-1221.00) | 262.10 (121.25-721.55) * | -59.4 | 39.76 (21.46-74.42) | 17.67 (14.04-36.20) * | -27.1 |
| 12-month treatment c | 15 | 9/1 | 56.40 ± 13.17 (14-82) | 45.67 ± 17.94 (29-83) | 287.00 (132.0-0779.00 | 63.00 (49.00-83.00) * | -73.6 | 612.00 (507.00-948.20) | 251.60 (155.70-457.40) * | -55.4 | 37.25 (20.68-45.2) | 24.20 (16.40-40.82) * | -33.4 |
a
Data are showed as mean ± standard deviation (range).
b
Data are showed as median (25th and 75th percentiles).
c
including one female patient with SQSTM1 mutation.
*p<0.05 when compared to baseline.
BTMs, bone turnover marker; No., Number; ALP, total alkaline phosphatase; β-CTX, β-CrossLaps of type 1 collagen containing cross-linked; OC, osteocalcin.